Quick Answer
AN2 Therapeutics, Inc. reported Research And Development Expense of $24.77 million for the year ending 2025.
- AN2 Therapeutics, Inc. showed a decrease of -38.8% in Research And Development Expense from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.65 million | Q2 2021: $3.85 million | Q3 2021: $5.35 million | Q1 2022: $5.63 million | Q2 2022: $6.70 million | Q3 2022: $7.43 million | Q1 2023: $11.99 million | Q2 2023: $13.54 million | Q3 2023: $14.43 million | Q1 2024: $14.66 million | Q2 2024: $12.15 million | Q3 2024: $8.29 million | Q1 2025: $7.69 million | Q2 2025: $3.20 million | Q3 2025: $7.00 million.
- Over the full 5 years of available data (2021 to 2025), AN2 Therapeutics, Inc.'s Research And Development Expense has grown by 53.3%.
- Historical annual values: Fiscal year 2025: $24.77 million | Fiscal year 2024: $40.49 million | Fiscal year 2023: $54.87 million | Fiscal year 2022: $28.51 million | Fiscal year 2021: $16.16 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: